|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01177 SINO BIOPHARM
Nominal 
5.890 +0.070 (+1.203%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 31,834,488 | 10.283% | 28,866,159 | 26,199,409 | 28,780,412 | 26,861,356 |
| Cost of Sales | (5,707,740) | 6.962% | (5,336,218) | (4,989,877) | (5,795,510) | (5,332,095) |
| Gross Profit | 26,126,748 | 11.036% | 23,529,941 | 21,209,532 | 22,984,902 | 21,529,261 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (151,376) | 27.961% | (118,299) | (525,710) | (152,976) | 13,630,790 | |
| Profit / (Loss) before Taxation | 6,943,396 | 31.567% | 5,277,468 | 5,409,906 | 5,778,604 | 18,572,673 | |
| Taxation | (1,628,867) | 230.454% | (492,918) | (797,267) | (775,986) | (1,957,880) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | 1,580,132 | 484,759 | -- | -- | |
| Non-controlling Interests | (2,971,181) | 3.712% | (2,864,848) | (2,765,459) | (2,459,048) | (2,006,381) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,343,348 | -33.044% | 3,499,834 | 2,331,939 | 2,543,570 | 14,608,412 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (355,278) | 73.775% | (204,447) | 116,902 | 237,617 | 146,560 |
| Depreciation & Amortisation | 1,211,583 | -8.295% | 1,321,181 | 1,036,695 | 1,046,984 | 992,556 |
| Directors' Emoluments | -- | -- | 205,314 | 203,407 | 227,139 | 176,656 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 13.020 | -31.939% | 19.130 | 12.590 | 13.660 | 77.830 |
| DPS (cts) | 9.102 | -- | 6.530 | 4.534 | 10.505 | 6.488 |
| Dividend Payout Ratio (%) | 69.908% | -- | 34.134% | 36.015% | 76.904% | 8.336% |
| Cash flow per share ($) | -- | -- | 0.362 | 0.327 | 0.336 | 0.286 |
| NBV per share ($) | 1.635 | -- | 1.701 | 1.621 | 1.581 | 1.608 |
| Remarks: | Real time quote last updated: 27/03/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,343,348 |
| %Change | -33.044% |
| EPS / (LPS) | RMB 0.130 |
| NBV Per Share (¥) | RMB 1.635 |